Werewolf Therapeutics Inc (HOWL) FinancialsHOWLFinancialWerewolf Therapeutics Inc

Evaluating the bottom line, Werewolf Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 40.65%, while the net margin is 17.48%. These profitability ratios, combined with a Return on Equity (ROE) of -119.86%, provide a clear picture of how effectively HOWL converts its operational activities into shareholder value.

In the context of the broader market, HOWL competes directly with industry leaders such as MGX and VERU. With a market capitalization of $48.05M, it holds a leading position in the sector. When comparing efficiency, HOWL's gross margin of 100.00% stands against MGX's 100.00% and VERU's N/A. Such benchmarking helps identify whether Werewolf Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company reported a net profit of $3.67 million for Q2 2026, a significant improvement from a loss of $17.98 million in Q2 2025. The gross margin for Q2 2026 stands at 100%, indicating strong profitability on revenue generated from collaboration agreements. The current ratio is 2.91, suggesting good short-term financial health.